Immediate Impact
8 standout
Citing Papers
Notch signaling pathway in cancer: from mechanistic insights to targeted therapies
2024 Standout
Cancer therapy with antibodies
2024 Standout
Works of Hugo Hool being referenced
Results of a randomized phase II trial of an anti-notch 2/3, tarextumab (OMP-59R5, TRXT, anti-Notch2/3), in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC).
2017
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Hugo Hool | 18 | 1 | 10 | 6 | 3 | 20 | ||
| Lidia Estudillo | 16 | 13 | 8 | 2 | 21 | |||
| Fumihiko Urushibara | 13 | 7 | 8 | 3 | 24 | |||
| Farzaana Adam | 14 | 7 | 4 | 3 | 21 | |||
| Mohamed Rezal Abdul Aziz | 21 | 10 | 3 | 3 | 27 | |||
| Greg Gydush | 9 | 9 | 17 | 3 | 24 | |||
| Florentia Fostira | 15 | 4 | 4 | 2 | 29 | |||
| Tomonari Cho | 14 | 7 | 8 | 3 | 24 | |||
| Esther Pohl‐Rescigno | 11 | 13 | 8 | 2 | 21 | |||
| Emilie Bouvignies | 12 | 1 | 14 | 13 | 3 | 28 | ||
| Sarah Vidito | 12 | 6 | 6 | 4 | 20 |
All Works
Loading papers...